Coronaviridae Infections
6
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
A Study to Explore the Role of Gut Flora in COVID-19 Infection
Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19
EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19